Gaxos.ai Ditches Gaming in High-Stakes Bet on AI and Health Tech

ROSELAND, NJ – July 28, 2026 – Gaxos.ai Inc. (NASDAQ: GXAI) has completed a dramatic strategic pivot, shedding its gaming division to double down on what it sees as its most promising frontiers: artificial intelligence applications and personalized health technology. The move follows a period of explosive top-line growth, with the company reporting first-quarter revenue of $1.81 million, a staggering leap from just $24,000 in the same period last year. By selling its gaming assets, Gaxos is making a clear, high-stakes bet that a leaner, more focused identity will translate a revenue surge into sustainable, long-term value.

This realignment marks a critical transition for the company, moving from a diversified portfolio-building phase to one centered on commercial execution. “The gaming divestiture marks an important transition from portfolio expansion to focused execution,” said Vadim Mats, Chief Executive Officer of Gaxos, in a statement. “Our priorities are straightforward: grow recurring and repeat revenue, improve the efficiency of customer acquisition, exercise discipline in deploying capital and provide shareholders with clearer messaging.” The question now facing investors and industry watchers is whether this sharpened focus can carve out a profitable niche in the hyper-competitive AI and health-tech sectors.

From Diversification to Discipline

The strategic shift was solidified with the sale of Gaxos's mobile game portfolio and its Gaxos Gaming Labs to the privately held Game Foundry AI. In exchange, Gaxos received 2.2 million shares of Game Foundry AI stock, valued at approximately $1.76 million at the time of the transaction. The deal allows Gaxos to retain a foothold in the gaming industry's potential upside through its equity stake while freeing up critical operating resources.

This decision appears to be a calculated move to improve financial discipline. While Gaxos doesn't release divisional profit figures, a pro forma analysis suggests the divestiture could significantly improve the company's bottom line. For the year ended December 31, 2025, the move is projected to shrink Gaxos’s net loss from $4.28 million to $2.54 million. This indicates the gaming division was likely a significant drag on profitability, and its removal is a key part of the new 'focused execution' mandate.

“This realignment is about focus, accountability and execution,” Mats emphasized. The company’s new operating priorities underscore this shift, with a stated intent to scale platforms with proven customer demand, rigorously evaluate marketing investments on payback and retention, and advance commercially oriented AI products. This disciplined approach is a stark contrast to the previous strategy of broad portfolio expansion, signaling a maturation of the company's business model.

The New Revenue Engines: Health Tech and AI Tools

The impressive Q1 revenue numbers reveal the two pillars of Gaxos's new strategy. The lion's share of the revenue, approximately $1.25 million, came from RNK Health, its majority-owned personalized health and wellness subsidiary. The remaining $563,000 was generated by subscriptions to AI applications from its Gaxos Labs division.

RNK Health is tapping into the booming personalized wellness market, which is projected to grow at a compound annual growth rate (CAGR) of over 15%. RNK provides non-clinical services that connect patients with medical and fulfillment partners for personalized weight loss, longevity, and performance treatments. However, while the business model is generating significant revenue, some market observers have critically described it as a "telehealth outfit hawking peptides and GLP-1 weight-loss scripts," questioning the depth of its technological innovation versus its role as a digital marketing and logistics platform for popular treatments.

Meanwhile, Gaxos Labs is building a suite of consumer and enterprise AI tools. Its current portfolio includes 'Art-Gen' for image and video creation, 'BiblePray' for personalized spiritual guidance, and 'UnGPT,' a tool designed to humanize AI-generated text to bypass detection software. The lab is also developing a more ambitious AI-powered sales coaching platform, supported by funding from Amazon's AWS, which aims to compete in a market projected to reach nearly $19 billion by 2034 against established players like Gong.io and Chorus.ai. The success of Gaxos Labs will depend on its ability to move from niche consumer apps to enterprise-grade solutions with scalable, recurring revenue models.

The High Cost of Growth

Despite the meteoric revenue growth, Gaxos.ai's path to profitability remains a significant challenge. The company is not yet profitable, reporting a net loss of $3.9 million in 2025, and analyst forecasts predict continued unprofitability for the next few years. This reality is reflected in the company's capital deployment. In the fourth quarter of 2025 alone, Gaxos spent $2.3 million on marketing for RNK Health and another $380,000 for Gaxos Labs—figures that dwarf the revenue generated in the same period.

This high cash burn rate is a central concern. The company's new strategic priority to improve customer-acquisition efficiency is not just a corporate goal; it is an existential necessity. Management will be under pressure to demonstrate that its marketing spend can generate a positive and timely return on investment, a metric that will be closely watched by investors. The stock market has reflected this uncertainty, with Gaxos's share price experiencing significant volatility and at least one analyst maintaining a "Sell" rating, citing concerns over negative free cash flow and a history of share dilution.

Strategic Bets and Future Trajectories

Beyond its two main operating divisions, Gaxos maintains strategic exposure to the defense technology market through a 19.99% ownership interest in America First Defense.AI LLC. This firm is developing next-generation counter-UAS and robotic platforms, and recently began deploying the advanced Anduril Lattice Platform. Gaxos plans to report on this investment separately, providing investors with a clearer distinction between its core operations and its strategic ventures.

By narrowing its focus to AI and health while maintaining a stake in the high-growth defense-tech sector, Gaxos is crafting a new narrative. It is a story of a company attempting to transition from a speculative, multi-pronged entity into a disciplined operator focused on commercially viable technologies. The impressive revenue growth provides a compelling first chapter, but the company must now prove that this growth can be converted into efficient, durable, and ultimately profitable operations. For Gaxos.ai, the pivot is complete; the period of execution has just begun.